CCDC85B

Summary

CCDC85B (coiled-coil domain containing 85B, HGNC:24926) is a protein-coding gene on chromosome 11q13.1, encoding Coiled-coil domain-containing protein 85B (Q15834). Functions as a transcriptional repressor.

Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids. Delta-interacting protein A (DIPA), a cellular gene product, has been found to have homology to hepatitis delta virus antigen (HDAg). DIPA interacts with the viral antigen, HDAg, and can affect HDV replication in vitro.

Source: NCBI Gene 11007 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 18 total
• MANE Select transcript: NM_006848

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24926
Approved symbol	CCDC85B
Name	coiled-coil domain containing 85B
Location	11q13.1
Locus type	gene with protein product
Status	Approved
Aliases	DIPA
Ensembl gene	ENSG00000175602
Ensembl biotype	protein_coding
OMIM	605360
Entrez	11007

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000312579

RefSeq mRNA: 1 — MANE Select: NM_006848 NM_006848

CCDS: CCDS8120

Canonical transcript exons

ENST00000312579 — 1 exons

Exon	Start	End
ENSE00001190339	65890673	65891635

Expression profiles

Bgee: expression breadth ubiquitous, 285 present calls, max score 98.32.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 121.4764 / max 1204.8596, expressed in 1827 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115233	115.2926	1827
115232	6.1838	1674

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
amygdala	UBERON:0001876	98.32	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.11	gold quality
right frontal lobe	UBERON:0002810	98.01	gold quality
nucleus accumbens	UBERON:0001882	97.83	gold quality
putamen	UBERON:0001874	97.82	gold quality
apex of heart	UBERON:0002098	97.80	gold quality
caudate nucleus	UBERON:0001873	97.57	gold quality
CA1 field of hippocampus	UBERON:0003881	97.37	gold quality
cingulate cortex	UBERON:0003027	97.36	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	97.29	gold quality
anterior cingulate cortex	UBERON:0009835	97.24	gold quality
right atrium auricular region	UBERON:0006631	97.14	gold quality
mucosa of stomach	UBERON:0001199	96.63	gold quality
cardiac atrium	UBERON:0002081	96.63	gold quality
ascending aorta	UBERON:0001496	96.46	gold quality
Ammon’s horn	UBERON:0001954	96.46	gold quality
thoracic aorta	UBERON:0001515	96.39	gold quality
orbitofrontal cortex	UBERON:0004167	96.28	gold quality
left uterine tube	UBERON:0001303	96.23	gold quality
temporal lobe	UBERON:0001871	96.13	gold quality
prefrontal cortex	UBERON:0000451	96.08	gold quality
descending thoracic aorta	UBERON:0002345	96.00	gold quality
right hemisphere of cerebellum	UBERON:0014890	96.00	gold quality
frontal cortex	UBERON:0001870	95.92	gold quality
frontal lobe	UBERON:0016525	95.91	gold quality
left coronary artery	UBERON:0001626	95.90	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	95.88	gold quality
telencephalon	UBERON:0001893	95.81	gold quality
coronary artery	UBERON:0001621	95.66	gold quality
Brodmann (1909) area 46	UBERON:0006483	95.65	gold quality

Single-cell (SCXA)

Detected in 17 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-MTAB-8271	yes	759.29
E-HCAD-38	yes	702.83
E-MTAB-8205	yes	452.13
E-MTAB-7037	yes	145.73
E-MTAB-10287	yes	61.76
E-HCAD-11	yes	45.31
E-HCAD-10	yes	39.84
E-CURD-46	yes	35.59
E-MTAB-8410	yes	33.95
E-HCAD-1	yes	31.70
E-MTAB-6701	yes	31.53
E-HCAD-9	yes	15.17
E-MTAB-10042	yes	13.46
E-CURD-112	yes	7.87
E-MTAB-9689	no	677.92

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

7 targeting CCDC85B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-6849-3P	97.25	64.57	1371
HSA-MIR-1202	97.19	66.43	827
HSA-MIR-3972	97.19	66.46	808
HSA-MIR-6872-3P	97.08	66.99	750
HSA-MIR-3194-5P	96.80	64.90	1027
HSA-MIR-6798-3P	94.55	68.78	325

Literature-anchored findings (GeneRIF, showing 3)

• DIPA is a novel partner of C/EBP beta that down-regulates early events of adipogenesis. (PMID:15644333)
• DIPA can act as a repressor of gene transcription, an activity that appears to be enhanced by p78. (PMID:17014843)
• High CCDC85B expression is associated with non-small cell lung cancer. (PMID:30242906)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ccdc85b	ENSDARG00000061543
mus_musculus	Ccdc85b	ENSMUSG00000095098
rattus_norvegicus	Fosl1	ENSRNOG00000020552
caenorhabditis_elegans		WBGENE00017931

Paralogs (2): CCDC85A (ENSG00000055813), CCDC85C (ENSG00000205476)

Protein

Protein identifiers

Coiled-coil domain-containing protein 85B — Q15834 (reviewed: Q15834)

Alternative names: Hepatitis delta antigen-interacting protein A

All UniProt accessions (1): Q15834

UniProt curated annotations — full annotation on UniProt →

Function. Functions as a transcriptional repressor. May inhibit the activity of CTNNB1 in a TP53-dependent manner and thus regulate cell growth. May function in adipocyte differentiation, negatively regulating mitotic clonal expansion. Plays a role in cell-cell adhesion and epithelium development through its interaction with proteins of the beta-catenin family. (Microbial infection) Plays a role in hepatitis delta virus (HDV) genomic replication.

Subunit / interactions. Interacts with CEBPB. Interacts with EURL. May interact with CEBPD. Interacts with MCRS1. Interacts with TCF7L2; competes with CTNNB1. Interacts with ANKRD26. Interacts with the beta-catenin family proteins ARVCF, CTNND1, CTNND2 and PKP4. (Microbial infection) Interacts with the viral phosphoprotein hepatitis delta antigen (HDAG); this interaction affects hepatitis delta virus (HDV) genomic replication in intact cells.

Subcellular location. Nucleus. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Cell junction. Adherens junction.

Tissue specificity. Widely expressed including liver.

Induction. Up-regulated by doxorubicin.

Miscellaneous. May be the cellular homolog of HDAG. Overexpression inhibited HDV replication, whereas overexpression of HDAG reversed the inhibition, suggesting that HDAG may assist HDV replication by forming a complex with DIPA.

Similarity. Belongs to the CCDC85 family.

RefSeq proteins (1): NP_006839* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019359	CCDC85	Family

Pfam: PF10226

UniProt features (9 total): coiled-coil region 2, compositionally biased region 2, chain 1, region of interest 1, modified residue 1, mutagenesis site 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15834-F1	83.15	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1

Mutagenesis-validated functional residues (1):

Position	Phenotype
131	loss of interaction with tcf7l2 and loss of suppression of ctnnb1 activity. loss of cell growth inhibition.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 166 (showing top): GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_YELLOW_DN, GOBP_REGULATION_OF_FAT_CELL_DIFFERENTIATION, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, MYOGENIN_Q6, GOBP_NEGATIVE_REGULATION_OF_FAT_CELL_DIFFERENTIATION, GCANCTGNY_MYOD_Q6, GOBP_NEGATIVE_REGULATION_OF_CELL_GROWTH, KAAB_HEART_ATRIUM_VS_VENTRICLE_UP, GOBP_GROWTH, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, chr11q13, CAGCTG_AP4_Q5, GOCC_MICROTUBULE_ORGANIZING_CENTER, TANG_SENESCENCE_TP53_TARGETS_UP, BROWNE_HCMV_INFECTION_48HR_DN

GO Biological Process (4): cell differentiation (GO:0030154), negative regulation of cell growth (GO:0030308), negative regulation of fat cell differentiation (GO:0045599), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (2): delta-catenin binding (GO:0070097), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), centrosome (GO:0005813), adherens junction (GO:0005912), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular developmental process	1
regulation of cell growth	1
cell growth	1
negative regulation of growth	1
negative regulation of cellular process	1
fat cell differentiation	1
negative regulation of cell differentiation	1
regulation of fat cell differentiation	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
centriole	1
microtubule organizing center	1
cell-cell junction	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membraneless organelle	1
cell junction	1

Protein interactions and networks

STRING

546 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC85B	ZNF358	Q9NW07	650
CCDC85B	CTNND1	O60716	521
CCDC85B	SOX18	P35713	504
CCDC85B	TCF7L2	Q9NQB0	450
CCDC85B	TRIM44	Q96DX7	447
CCDC85B	ZBTB16	Q05516	437
CCDC85B	HOMER3	Q9NSC5	433
CCDC85B	OIP5	O43482	426
CCDC85B	ARHGAP23	Q9P227	421
CCDC85B	ZNF575	Q86XF7	414
CCDC85B	ZIC1	Q15915	404
CCDC85B	NKX1-1	Q15270	396
CCDC85B	FASN	P49327	389
CCDC85B	SNCA	P37840	387
CCDC85B	ARHGAP21	Q5T5U3	386

IntAct

208 interactions, top by confidence:

A	B	Type	Score
PPP1CC	CCDC85C	psi-mi:“MI:0914”(association)	0.740
PPP1CC	CCDC85C	psi-mi:“MI:2364”(proximity)	0.740
PPP1CA	CCDC85C	psi-mi:“MI:0914”(association)	0.670
PPP1CA	CCDC85C	psi-mi:“MI:2364”(proximity)	0.670
SKA3	NOL4	psi-mi:“MI:0914”(association)	0.640
CCDC85B	FAM74A4	psi-mi:“MI:0915”(physical association)	0.560
CCDC85B	ZNF564	psi-mi:“MI:0915”(physical association)	0.560
CCDC85B	ODAD4	psi-mi:“MI:0915”(physical association)	0.560
FAM74A4	CCDC85B	psi-mi:“MI:0915”(physical association)	0.560
ODAD4	CCDC85B	psi-mi:“MI:0915”(physical association)	0.560
ZNF564	CCDC85B	psi-mi:“MI:0915”(physical association)	0.560
THP2	CCDC85B	psi-mi:“MI:0915”(physical association)	0.560
CCDC85B	THP2	psi-mi:“MI:0915”(physical association)	0.560
CCDC85B	ZNF587	psi-mi:“MI:0915”(physical association)	0.560
CCDC85B	INO80B	psi-mi:“MI:0915”(physical association)	0.560
RGS8	CCDC85B	psi-mi:“MI:0915”(physical association)	0.560
CCDC85B	CENPP	psi-mi:“MI:0915”(physical association)	0.560
BIRC5	CCDC85B	psi-mi:“MI:0915”(physical association)	0.560
MAGEA4	MAGEB16	psi-mi:“MI:0914”(association)	0.530
SKA3	CCDC85C	psi-mi:“MI:0914”(association)	0.530
TSKS	RGPD8	psi-mi:“MI:0914”(association)	0.530

BioGRID (192): TTC25 (Two-hybrid), ZNF564 (Two-hybrid), FAM74A4 (Two-hybrid), CCDC85B (Affinity Capture-MS), CCDC85B (Affinity Capture-MS), CCDC85B (Affinity Capture-MS), FAM27E3 (Two-hybrid), ZNF250 (Two-hybrid), KANSL1 (Two-hybrid), CCDC85B (Two-hybrid), CCDC85B (Affinity Capture-MS), PBXIP1 (Two-hybrid), ZNF821 (Two-hybrid), NIF3L1 (Two-hybrid), CCDC85B (Two-hybrid)

ESM2 similar proteins: A4FV37, A4IFI1, A5D8V7, A6NC98, A6NFT4, A6NGB0, A6QQM8, A9UQN0, B0BMJ2, B0BNK9, D3Z5T1, D6REC4, J3QPZ5, O00411, O60826, O94812, P0C7Q1, P0CW27, P86182, Q0P5D1, Q13515, Q15834, Q17Q97, Q1RMI8, Q2M329, Q3V3V9, Q494R4, Q4QRL3, Q571B6, Q58EX7, Q5BK61, Q5FVL4, Q5ND29, Q5SPX1, Q66H85, Q6F5E8, Q6NTM6, Q6PDY0, Q7TMK6, Q80ZJ8

Diamond homologs: A2CEM9, A6NKD9, E9Q6B2, H2KYP0, Q0P485, Q0V989, Q15834, Q4V872, Q5SP85, Q6DHL7, Q6PDY0, Q96PX6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

18 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

34 predictions. Top by Δscore:

Variant	Effect	Δscore
11:65890847:G:GT	donor_gain	0.6600
11:65890925:G:GT	donor_gain	0.4900
11:65890991:C:CT	acceptor_gain	0.3800
11:65890992:T:TT	acceptor_gain	0.3800
11:65890903:G:GA	acceptor_gain	0.3500
11:65890843:C:T	donor_gain	0.3400
11:65890900:GGTGC:G	acceptor_gain	0.3400
11:65890901:G:A	acceptor_gain	0.3400
11:65890985:CGGCG:C	acceptor_gain	0.3400
11:65890899:TGGTG:T	acceptor_gain	0.3000
11:65890919:A:AT	acceptor_gain	0.3000
11:65890920:T:TT	acceptor_gain	0.3000
11:65890986:G:GT	acceptor_gain	0.2900
11:65890987:G:T	acceptor_gain	0.2800
11:65890995:A:AG	acceptor_gain	0.2700
11:65890996:G:GG	acceptor_gain	0.2700
11:65891002:GAACC:G	donor_gain	0.2700
11:65891410:C:CA	acceptor_gain	0.2700
11:65890932:A:G	donor_gain	0.2600
11:65890915:C:CT	acceptor_gain	0.2500
11:65890937:CAG:C	acceptor_gain	0.2400
11:65891011:G:GT	donor_gain	0.2400
11:65891034:T:TA	acceptor_gain	0.2400
11:65890989:G:T	acceptor_gain	0.2200
11:65890990:T:TT	acceptor_gain	0.2200
11:65890997:G:GT	donor_gain	0.2200
11:65890998:C:T	donor_gain	0.2100
11:65891325:G:GT	donor_gain	0.2100
11:65890789:G:T	acceptor_gain	0.2000
11:65890934:CGGCA:C	acceptor_gain	0.2000

AlphaMissense

1271 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:65891327:A:C	S182R	0.998
11:65891329:C:A	S182R	0.998
11:65891329:C:G	S182R	0.998
11:65890971:T:C	L63P	0.997
11:65891325:G:A	G181E	0.997
11:65890992:T:C	L70P	0.995
11:65891013:T:C	L77P	0.995
11:65891197:G:C	K138N	0.995
11:65891197:G:T	K138N	0.995
11:65890941:T:C	L53P	0.994
11:65891333:A:C	S184R	0.994
11:65891335:C:A	S184R	0.994
11:65891335:C:G	S184R	0.994
11:65891022:T:C	L80P	0.992
11:65891324:G:A	G181R	0.992
11:65891324:G:C	G181R	0.992
11:65891328:G:A	S182N	0.992
11:65891342:A:C	S187R	0.992
11:65891344:C:A	S187R	0.992
11:65891344:C:G	S187R	0.992
11:65891322:A:T	D180V	0.991
11:65890975:G:C	K64N	0.990
11:65890975:G:T	K64N	0.990
11:65891328:G:T	S182I	0.990
11:65890866:T:C	L28P	0.989
11:65891075:T:A	W98R	0.987
11:65891075:T:C	W98R	0.987
11:65891077:G:C	W98C	0.987
11:65891077:G:T	W98C	0.987
11:65891325:G:T	G181V	0.987

dbSNP variants (sampled 300 via entrez): RS1001384988 (11:65888785 T>A), RS1002794877 (11:65889576 A>C,T), RS1003077274 (11:65889913 T>C), RS1003462978 (11:65890158 TC>T,TCC), RS1003816107 (11:65890642 G>A,C), RS1003866930 (11:65890522 AG>A,AGG), RS1005020441 (11:65892088 G>A), RS1005156329 (11:65891874 A>G,T), RS1005188812 (11:65888678 C>A,T), RS1005504228 (11:65892071 C>T), RS1005543507 (11:65891765 G>A), RS1007572231 (11:65888790 G>A,C), RS1008161852 (11:65890469 G>C), RS1008440374 (11:65890647 G>A,T), RS1009292964 (11:65889431 AT>A,ATT,ATTT)

Disease associations

OMIM: gene MIM:605360 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002481_8	Acne (severe)	3.000000e-11
GCST009798_25	Asthma	2.000000e-09
GCST90020028_2000	Hip circumference adjusted for BMI	3.000000e-10

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression, increases expression	4
Silicon Dioxide	increases expression	3
Acetaminophen	affects cotreatment, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Cisplatin	decreases expression, affects response to substance, affects cotreatment	2
aristolochic acid I	increases expression	1
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	decreases expression	1
testosterone enanthate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	increases expression	1
zinc chromate	decreases expression, increases abundance	1
vanadyl sulfate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression, increases abundance	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
jinfukang	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Atrazine	increases expression	1
Chenodeoxycholic Acid	affects cotreatment, increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Deoxycholic Acid	affects cotreatment, increases expression	1
Diethylstilbestrol	decreases expression	1
Estradiol	increases expression	1
Ethyl Methanesulfonate	decreases expression	1
Formaldehyde	decreases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Glycochenodeoxycholic Acid	affects cotreatment, increases expression	1
Glycocholic Acid	affects cotreatment, increases expression	1
Glycodeoxycholic Acid	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.